Kinetics of NK cells and monocytes before and during therapy in cHL and DLBCL. (A) Proportion of NK-cell and monocyte subsets pretherapy and after 3 cycles of ABVD in patients with cHL. (B) Proportion of NK cell and monocyte subsets pretherapy and after 4 cycles of R-CHOP in patients with DLBCL. Percentages are of total numbers of CD56^hiCD16⁻ NK cells, CD56^dimCD16⁺ NK cells, and CD163⁺ monocytes, respectively.